It is widely reported that healthcare is a top antitrust enforcement priority in the U.S. The healthcare industry has undergone a transformation over the over the last twenty years and now comprises 17.7% of the U.S. gross domestic product and over $3.795 trillion of the U.S. government budget. Mega-deals among national payors and household names have grabbed headlines and been targets of enforcement by the U.S. Department of Justice, Antitrust Division (the “DOJ”) and Federal Trade Commission (“FTC”) (collectively, “the Agencies”).
More Posts
Private Equity & Healthcare: Antitrust Enforcement in 2023–PE Roll-Ups in the Cross Hairs
CMS Includes MAOs in Data Exchange and Prior Authorization Requirements
Pharmaceutical Manufacturers Ask EDVa to Allow Cost-Sharing Under the AKS
Senate Committee Issues Report On Deceptive Marketing Practices in Medicare Programs
CMS Heightens Oversight of TPMO Marketing Programs, Restricts TV Advertisements
2023 Payment Rule’s Nondiscrimination Provisions and Anticipation of New Section 1557 Rules
Medicaid and Health Equity: CalAIM’s Bold Experiment
CMS Proposes to Revise, Again, the Stark Law’s Definition of “Indirect Compensation Arrangement”: What Was Old is New Again
CMS Proposes to Revise, Again, the Stark Law’s Definition of “Indirect Compensation Arrangement”: What Was Old is New Again
Subscribe: Subscribe via RSS